FCMV
LYEL icon

Foresite Capital Management V’s Lyell Immunopharma LYEL Stock Holding History

Foresite Capital Management V’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69M Sell
476,386
-692
-0.1% -$12.5K 1.85% 8
2026
Q1 		$9.57M Hold
477,078
– – 3.53% 6
2025
Q4 		$14.7M Hold
477,078
– – 8.93% 5
2025
Q3 		$7.75M Buy
477,078
+70,426
+17% +$804K 7.12% 5
2025
Q2 		$3.59M Hold
406,652
– – 4.45% 6
2025
Q1 		$4.38M Hold
406,652
– – 4.99% 5
2024
Q4 		$5.21M Buy
+406,652
New +$8.06M 4.33% 6

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Foresite Capital Management V's LYEL Position: Q2 2026 in Review

Foresite Capital Management V reduced its Lyell Immunopharma (LYEL) stake by 0.15% in Q2 2026, selling an estimated $12.5K and leaving 476,386 shares worth $6.69M. The position accounts for 1.85% of the portfolio, ranked #8.

Foresite Capital Management V first reported a position in LYEL in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.7M in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Foresite Capital Management V held 476,386 shares of Lyell Immunopharma worth $6.69M as of Q2 2026.
  • Foresite Capital Management V sold 692 Lyell Immunopharma shares in Q2 2026, an estimated $12.5K.
  • Lyell Immunopharma made up 1.85% of Foresite Capital Management V's portfolio in Q2 2026, its #8 holding.
  • Foresite Capital Management V first reported a position in Lyell Immunopharma in Q4 2024 and has held it in 7 quarters since.
  • Foresite Capital Management V's Lyell Immunopharma position peaked at $14.7M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Foresite Capital Management V's 13F filing for Q2 2026, filed 14 Aug 2026.